Northwest Biotherapeutics' brain cancer treatment, DCVax, has been under review for over 931 days after submitting a marketing application to the U.K.'s Medicines and Healthcare products Regulatory Agency in late December 2023.[3298197] The FDA approved Vera Therapeutics' kidney disease drug, Trutakna, for patients with IgA nephropathy, a type of chronic autoimmune kidney disease, on July 7, 2026.[3063198] Vera Therapeutics' CEO Marshall Fordyce stated that the company is 'extremely excited' to bring Trutakna to patients and expects it to be a game-changer in treatment for IgA nephropathy.[3063198]